UFP Technologies reports record Q1: revenue $148.1M (+41%), net income $17.2M (+35%), EPS $2.21

UFP TECHNOLOGIES INC

2025-Q1 EPS reported $2.21 revenue$148,148,000

Net sales $148.1M vs $105.0M (+41.1%); MedTech sales up 50.4% to $135.4M.
GAAP diluted EPS $2.21 vs $1.64; adjusted EPS $2.47 vs $1.77; adjusted EBITDA $30.2M (+45.9%).
MedTech organic growth 5.4% despite 6% Robotic Surgery decline; overall organic growth 2.3%.
Exclusive manufacturing agreement with second-largest customer for Safe Patient Handling through June 2030; Dominican Republic expansion.
Closed small fold-in acquisition (former sister company of AJR); balance sheet strengthened with debt paydown.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001171843-25-002859
form_type: 8-K
ticker: UFPT
cik: 0000914156
company_name: UFP TECHNOLOGIES INC
filed_at: 2025-05-07T23:59:59+00:00
discovered_at: 2026-05-14T18:02:51.789777+00:00
generated_at: 2026-05-22T10:20:06.655820+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: positive
materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001171843-25-002859
json_url: https://secwatch.observer/filing/0001171843-25-002859.json
markdown_url: https://secwatch.observer/filing/0001171843-25-002859.md
text_url: https://secwatch.observer/filing/0001171843-25-002859.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/914156/000117184325002859/0001171843-25-002859-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/914156/000117184325002859/f8k_050725.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001171843-25-002859

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.